edition (DSM-5), autism spectrum disorders (ASD) are neurodevelopmental disorders whose core clinical features are persisting deficits in social communication and interaction as well as restricted, repetitive behaviors, interests, and activities. [1] Today, there are no biomarkers for ASD, whose diagnosis is still strictly clinical. [2] In 2013 DSM-5 introduced several innovations in the ASD nosography, including some appreciable changes such as the grouping of the symptoms related to social interaction and communication into one category (being recognized the necessary social nature of communication); symptoms concerning sensory issues have been given more weight (see hyper-or hypo-reactivity to sensory input); and the possibility that behavioral criteria are met based on history. [1] But alongside these favorable aspects, there are also a series of troubles. DSM-5 deleted the subdivision into 5 diagnostic subcategories (see DSM 4 th Edition Text Revision [DSM-IV-TR]: [3] autistic disorder, Asperger disorder, Rett disorder, childhood disintegrative disorder, and pervasive developmental disorder not otherwise specified), encompassing in a single diagnostic category a large number of conditions that appear very heterogeneous due to (1) the severity and complexity of the characteristic ASD symptoms; (2) the conditions that may occur in comorbidity (primarily intellectual disability); (3) and the underlying etiologies. All this in our opinion did not provide sufficient clarification neither in terms of clinical practice nor of research. Meanwhile, there are a lot of clinical features that justify the nosographic identity and autonomy of ASD; at the same time, the phenotypic differences among the ASD cases can be extremely significant. In fact, this broad diagnostic category may include very solitary and yet ingenious individuals who can also play a role of great responsibility in the society, as well as cases affected by severe encephalopathy with serious comorbid medical conditions, in which the presence of atypical behaviors leads to an ASD diagnosis. In view of this situation, in our opinion, the separation implemented in the DSM-5 into 3 subgroups according to severity (subjects requiring support, substantial support, and very substantial support correspond to level 1, 2, and 3, respectively) [1] appears simplistic and without any contribution to the qualitative characterization of ASD. As we previously pointed out, to make a reliable prognosis and plan an individualized treatment for these patients, it is important to consider not only the intensity but also the quality of symptoms. [4] An example of this is the differences in the cognitive profile that can be found between those patients who once according to DSM-IV-TR would receive a diagnosis of autistic disorder ("high-functioning") and those who would receive a diagnosis of Asperger disorder, but who all now fall into an ASD (usually severity level 1) according to DSM-5. [1] On the other hand, while according to the DSM-5 intellectual disability appears as one of the most important associated conditions in patients with ASD, the DSM-5 subdivision into four severity groups (mild, moderate, severe, and profound) of intellectual disability is based on descriptive criteria concerning adaptive functioning in the domains of conceptualization, socialization, and practical skills and no longer on the intelligence quotient (as it was the case according to the DSM-IV-TR). [1, 3] However, it is known that the adaptive abilities of individuals with ASD are impaired by definition, so that in cases with ASD and comorbid intellectual disability (association far from rare) we cannot understand to what extent the social maladjustment can be attributed to autism itself or to the cognitive deficit. Therefore, the prognostic value of the intellectual level in cases with ASD is somewhat questionable and difficult to establish.
These are some of the issues related to the DSM-5 and ASD that are still open and require an in-depth discussion by specialists who deal with these disorders.
Mucolipidosis Type II Secondary to GNPTAB Gene Deletion from India
Dear Sir, Mucolipidosis II (ML II) is a rare autosomal recessive disorder of lysosomal metabolism. It has often been clinically misdiagnosed as mucopolysaccharidosis. ML II is characterized by developmental delay, short stature, coarse facial features, and dysostosis multiplex. [1] We are reporting 9-month-old girl born to a second degree consanguineously married couple presented with developmental delay and noisy breathing. Examination revealed coarse facies, thick eyebrows, hypertelorism, bilateral corneal clouding, pectus excavatum, and kyphosis. There was hepatosplenomegaly but no cherry red spot. On investigations, thyroid function test and urine glycosaminoglycans were normal. Skeletal survey shows kyphosis of dorsal spine. Magnetic resonance imaging brain shows mild cerebral atrophy. Enzyme analysis in plasma shows elevated, alpha-mannosidase12,970 (normal: 20-120)-nmol/h/ml, alpha-fucosidase-6624 (normal: 90-610)-nmol/h/ml, and beta-hexosaminidase-T-23090 (normal: 620-4990) nmol/h/ml. High levels are suggestive of ML II/III. GNPTAB gene testing revealed a homozygotic deletion in exon 19 (c_3503_3504delTC). Based on severe MPS phenotype in early infancy, enzyme assay, and genetic testing, we diagnosed the case as ML II.
ML II is caused by deficiency of N-acetylglucosmine -1-phosphottransferase. This enzyme deficiency can produce two different phenotypes, ML II and ML III (pseudo-Hurler polydystrophy). [2] ML II and III differ in age of onset with ML II being present at birth and ML III starting clinical symptoms between 3 and 5 years of age. ML II causes severe intellectual disability, coarse facial features, skeletal abnormalities, and an early death during first decade. ML III is a late onset with variations in intellectual disability (normal to decreased), skeletal abnormalities which are prominent and these individuals may live for a number of decades. Based on above differences, we considered possibility of ML II in our child. [3] We excluded MPS based on early infancy presentation and absent of glycosaminoglycans in the urine. We ruled out congenital hypothyroidism based on normal thyroid function tests. We also excluded GM1 gangliosidosis and Sialidosis as child had no startle response, epilepsy, and cherry red spot in the fundus. Cury et al. reported mutation c_3503_3504delTC located in exon 19 was most common mutation (n = 11/24) in ML II and III in Brazil. [4] This mutation from Indian subcontinent is useful for the molecular diagnosis of ML II in India.
ML II should be considered as one of the differential diagnoses in patients presenting in early infancy with MPS phenotype. ML II is differentiated from ML III based on severe and early presentation in former.
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